Healthcare of Ontario Pension Plan Trust Fund Sells 149,092 Shares of Illumina, Inc. (NASDAQ:ILMN)

Healthcare of Ontario Pension Plan Trust Fund trimmed its stake in Illumina, Inc. (NASDAQ:ILMN) by 98.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,908 shares of the life sciences company’s stock after selling 149,092 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Illumina were worth $399,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Bouvel Investment Partners LLC raised its stake in shares of Illumina by 1.3% in the 1st quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock valued at $899,000 after acquiring an additional 84 shares in the last quarter. STF Management LP grew its holdings in Illumina by 3.5% in the 4th quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock valued at $368,000 after buying an additional 90 shares during the last quarter. Global Retirement Partners LLC grew its holdings in Illumina by 12.3% in the 1st quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock valued at $118,000 after buying an additional 94 shares during the last quarter. Gulf International Bank UK Ltd grew its holdings in Illumina by 0.7% in the 1st quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock valued at $1,862,000 after buying an additional 98 shares during the last quarter. Finally, Clear Creek Financial Management LLC grew its holdings in Illumina by 6.3% in the 4th quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after buying an additional 100 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of ILMN stock opened at $117.30 on Friday. The stock’s fifty day simple moving average is $109.69 and its 200 day simple moving average is $124.39. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a market cap of $18.69 billion, a price-to-earnings ratio of -14.39 and a beta of 1.15. Illumina, Inc. has a one year low of $89.00 and a one year high of $195.64.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. Illumina’s quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.08 EPS. On average, analysts expect that Illumina, Inc. will post 1.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of research analyst reports. Evercore ISI lowered their target price on Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a report on Tuesday, June 11th. Jefferies Financial Group initiated coverage on Illumina in a report on Monday, June 3rd. They issued a “hold” rating and a $115.00 target price on the stock. Robert W. Baird raised their target price on Illumina from $125.00 to $128.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. StockNews.com started coverage on Illumina in a report on Sunday, June 30th. They issued a “buy” rating on the stock. Finally, Royal Bank of Canada decreased their price objective on Illumina from $249.00 to $242.00 and set an “outperform” rating on the stock in a report on Monday, July 1st. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus price target of $158.57.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.